Abstract
BackgroundIn clinical trials, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) demonstrated durable efficacy in maintaining viral suppression, even in the presence of NRTI resistance-associatedmutations (RAMs). Little is known about the prevalence of RAMs and...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
